2 H.B. 4084, the Pharmaceutical Availability and Affordability Act, created the West Virginia Pharmaceutical Cost Management Council in 2004. W.Va. Code.

Slides:



Advertisements
Similar presentations
Fredrick H. Armstrong, Director, Archives & History Staff, Records Management and Preservation Board Records Management for Licensing Boards.
Advertisements

Alabama Primary Health Care Association
Introduction to Existing State Disclosure Laws and Regulations Summit on Disclosure, Transparency and Aggregate Spend For Drug, Device and Biotech Companies.
Issues and Compliance Strategies Related to Government Pricing Joseph W. Metro.
Trend in Prescription Drug Abuse In 2004, 19.1 million Americans were current illicit drug users (7.9% of the U.S. population) 1 In 2004, 19.1 million.
OMB Regulatory Requirements Regulatory Requirements 2. Written Policies & Procedures 3. Documen- tation of Expenses 4. Managing Cash 5. Efficient.
Impact of JUSFTA on affordability and availability of medicines from perspective of local generic manufacturers Towards equitable and affordable medicine.
JFDA & HAI Workshop Towards equitable and affordable medicine prices policy in Jordan 4-5 December 2007 Strategies to aid market entry and competition.
1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
Drug Information for Consumers and Healthcare Professionals Food and Drug Law Institute Annual Meeting Alan Goldhammer, PhD Associate VP Regulatory Affairs.
Assistive Technology Funding From A to Z: Considering Your Options [Event Title] [Event Location] [Date] Authors: Mel Grant, AT Advocate, SCRS, Martin.
1 October 16, Secretary of the Department of Administration, Chair Director of the Public Employees Insurance Agency Secretary of the Department.
NSAA/NASC Joint Middle Management Conference Kansas Taxpayer Transparency Act April 20, 2009.
WHO Good Distribution Practices for Pharmaceutical Products
August 28, 2009 Federal Emergency Management Agency Public Assistance Arbitration Process.
Session I Chapters 1-5 Presented by… Lynn Boyer, Ph.D.
The Make Medicare Work Coalition Governors Conference on Aging December 2009.
1 Targeted Case Management (TCM) Changes Iowa Medicaid Enterprise October 14, 2008.
New Title I/NCLB Directors Workshop NCLB Winter Conference January 16, 2007 Alaska Department of Education & Early Development Margaret MacKinnon, Title.
Title I Site Eligibility Ranking & Serving Schools NCLB Technical Assistance Audio March 28, :30 PM March 29, :30 AM Alaska Department of.
Webinar: June 6, :00am – 11:30am EDT The Community Eligibility Option.
Presented by the Illinois Department of Insurance Andrew Boron, Director November 2012.
Section 17.2 Sales Promotion
Copyright © 2012 Pearson Canada Inc. CHAPTER 13 Sales Promotion 13-1.
*Be prepared to discuss with the class!*
CCHSA Accreditation: New Standards for Managing Medications
Presented by : Yoel Finkel Central Bureau of Statistics, Israel OECD STESEG Meeting, Paris, Sept Credit-Card Purchases as a Short-Term Indicator.
What is NAP? NAP is a program of the State of Indiana in which tax credits are distributed to eligible non profits for sale as a fundraising and capacity.
1 Payment Systems Funds Availability Problems. 2 Problems Funds Availability Scenarios All deposits made in Oklahoma City on Monday March 1 Bank open.
Pharmaceutical and Medical Device Manufacturer Conduct Melissa J. Lopes, Deputy General Counsel Massachusetts Department of Public Health.
Net Price Calculator Presented by American Student Assistance.
Federal Tort Claims Act (FTCA) Free Clinics Program Technical Assistance Call Department of Health and Human Services Health Resources and Services Administration.
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
Title VI and Fares March 18, 2013 Jonathan Ocana Equal Opportunity Specialist.
HOWARD COMMUNITY COLLEGE FINANCIAL AID SERVICES You Can Afford College! 1.
Health Care 101 Understanding the Basics Marianne Monfils, CSEA Bryce Van De Moere, Esq. TPA, SCEET.
Karmen Hanson, MA Senior Policy Specialist National Conference of State Legislatures Audioconference The New California State Law and Other State Laws.
1 APCD Analytical Workgroup April 30,
Time and Effort Reporting
 Created by City Council in October Original purpose of the fund: To support housing opportunities for workforce families. $600,000 fund.  On.
Federal and State Monitoring Title I Directors Conference September
“Medication Units” (Opioid Treatment Programs) Drug Enforcement Administration James “Jim” Arnold Chief, Policy Unit Office of Diversion Control D E A.
Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Board Meeting April 8, 2015.
Marketing to Doctors – Payments for Loyalty Julie Brill Assistant Attorney General Vermont Attorney General ’ s Office Montpelier,
Pharmaceutical Compliance Congress: “State of the States” October 27, 2008 Janice G. Cunningham Jeffrey L. Handwerker.
1 Physician-Industry Transparency: The U.S. Physician Payment Sunshine Act.
House Bill 2437 Health Carrier Access Payment Commissioner Kim Holland Oklahoma Insurance Department.
1 PREPARING FORM 5500 SCHEDULE C A Presentation of The Profit Sharing/401k Council of America, The Securities Industry and Financial Markets Association.
PBM Transactions Medicaid DRA Rule –Proposed Rule AMP includes “Discounts, rebates or other price concessions to PBMs associated with sales for drugs provided.
Lobbying In Maine. When do you Become a “Lobbyist” and have to Register? 1.Must communicate with a covered governmental official 2.For the purpose of.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas.
© 2012 Medical Mutual of Ohio Fees and Taxes in Healthcare Reform Patricia Decensi Vice President, Assistant General Counsel Medical Mutual of Ohio.
Highest quality medications… Lowest possible cost.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
© 2008 Foley Hoag LLP. All Rights Reserved. 1 The New Massachusetts Pharmaceutical & Medical Device Marketing Regulations How to Address and Overcome Likely.
FUNDING MENTAL HEALTH SERVICES IN CALIFORNIA August 13, 2015.
COLORADO FAMILY PLANNING PROGRAM EXPENDITURE REVENUE REPORT (ERR) Presented on 12/16/13 by Abigail Aukema.
+ Role of Industry in Clinical Care, Research, and Education.
The Physician - Pharma Relationship.  Is very old and very close  But are the goals of pharmaceutical companies and medicine the same?
The Physician Payments Sunshine Act Legislation Ann Leopold Kaplan October 27, 2008.
California’s New Compliance Law Kelly N. Reeves
Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,
1 CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: INAGURAL MEETING COURTYARD.
Medicaid Influence in the Drug Market Dana Costea PhD student, Department of Economics, Lehigh University Franklin Carter Assistant Professor, Marketing.
Changes to AMP & Best Price: Impact on 340B Pricing February 1, 2008 Long Beach, California 4 th Annual 340B Coalition Winter Conference University of.
Analysis of the Proposed Sunshine Rule: Legal Considerations
Buccaneers SAIL Safe Accountable In Control Lead by Example.
ආහාර පනත සහ රෙගුලාසි.
If it's Subsidized, Get it Authorized: New Restrictions on the Sale and Use of PHI for Marketing Purposes Under HIPAA's Omnibus Rule Angela M. Rust This.
Presentation transcript:

2 H.B. 4084, the Pharmaceutical Availability and Affordability Act, created the West Virginia Pharmaceutical Cost Management Council in W.Va. Code 5A-3C-13 directs the Council to promulgate a rule to collect pharmaceutical advertising data The statute states that the data will enable the state to determine the scope of advertising costs and aide the state in purchasing drugs effectively. Why is reporting necessary?

3 All drug manufacturers and/or labeler whose prescription drugs are dispensed in West Virginia or to a West Virginia resident. 5A-3C-3 (4) Drug Manufacturer or pharmaceutical manufacturer means any entity which is engaged in (A) the production, preparation, propagation, directly or indirectly by extraction from substances of natural origin, or independently by means of chemical syntheses or by a combination of extraction and chemical syntheses; or (B) the packaging, repackaging, labeling, relabeling or distribution of prescription drug products. Drug manufacturer or pharmaceutical manufacturer does not include a wholesale distributor of drugs or a retail pharmacy licenses under state law. 5A-3C-3 (7) Labeler means an entity or person that receives prescription drugs from a manufacturer or wholesaler and repackages those drugs for later retail sale and that has a labeler code from the federal Food and Drug Administration pursuant to 21 CFR § (1999) Who must report?

4 The Company must list the total number of West Virginia prescribers provided directly or indirectly, gifts, grants, or payments of any kind in excess of $100 for the purpose of advertising prescription drugs. Annual payments in excess of $100 must be reported in increments of $2,500 until all payments to providers made by the company are reported What must be reported? Payments to Prescribers

5 What Must Be Reported? Payments to Prescribers Table Annual aggregate amount of fees, food, entertainment, recreational activities, travel expenses, gifts, grants or other payments Total Number of Prescribers

6 The name of any prescription drugs advertised using DTC advertising reaching or targeting West Virginia, the type of advertising used and the total amount spent. For national and regional media buys, the Company should report WVs share by the following formula: Total spent x (population of target area/population of WV) = WV share What must be reported? Direct-to-Consumer Advertising

7 What must be reported? Direct-to-Consumer Table Name of Drug (chemical name and brand name) Type of AdvertisingTotal Expenditure on Advertising

8 Company must list the name of any disease-specific patient support or advocacy group operating in West Virginia which received directly or indirectly gifts, grants, or payments of any kind totaling $10,000 or more for the purpose of advertising prescription drugs. What must be reported? Payments to Patient Support or Advocacy Groups

9 What must be reported? Payments to Patient Support or Advocacy Group Table Name of Advocacy GroupAmount of Annual Payments

10 Company must list the name of any pharmacy licensed in West Virginia which received directly or indirectly gifts, grants, or payments of any kind totaling $10,000 or more for the purpose of advertising prescription drugs. What Must be Reported? Payments to Pharmacies

11 What Must be Reported? Payments to Pharmacies Table PharmacyType of AdvertisingAmount of Payment

12 Companies may but are not required to report the following exempted information described in 5A-3C- 13(c). Free samples intended for patients Payments, compensation and reimbursement in connection with a bona-fide clinical trial Scholarship or other support for medical students, residents and fellows to attend significant education, scientific or policy-making conferences What is exempted from reporting?

13 First report is due March 1, 2008 for period from July 1, 2007 to December 31, Reports due each year thereafter on April 1 for the preceding calendar year. For first report, all reporting thresholds are prorated to reflect the 6-month period. Report shall be mailed to: West Virginia Pharmaceutical Cost Management Council c/o West Virginia Department of Administration Capitol Complex, 1900 Kanawha Boulevard, East Charleston, West Virginia When and where is the report due?

14 Pharmaceutical Availability and Affordability Act Title 206 Series 1, Prescription Drug Expense Reporting Where can the statute and rule be found?

15 Shana Phares, Pharmaceutical Advocate and Designated Chair, Pharmaceutical Cost Management Council or Bill Hicks, Assistant General Counsel, Department of Administration and Counsel to the Pharmaceutical Cost Management Council or Who can answer questions?